RxDoctor Payments Data

Craig Miller

Physician Assistant · Schenectady, NYNPI 1659325397

Payments from drug & device makers

$3,791in general payments, 2019–2025

Across 152 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$447
  • Novartis$348
  • AstraZeneca$337
  • Esperion Therapeutics, Inc.$311
  • Amgen$283
  • Boston Scientific$264
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$3,778100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,791 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$68,303
Medicare patients
877
Services billed
1,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban184$218,615
EntrestoSacubitril/Valsartan47$44,760
XareltoRivaroxaban27$34,825
Repatha SureclickEvolocumab31$21,569
BrilintaTicagrelor14$14,774
JardianceEmpagliflozin14$14,398
FarxigaDapagliflozin Propanediol14$10,884
Metoprolol Succinate204$2,962
Atorvastatin Calcium143$1,904
Torsemide96$1,781
Potassium Chloride34$890
Rosuvastatin Calcium51$745
Amlodipine Besylate102$716
Losartan Potassium37$568
Ezetimibe16$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$213$218,615184 claims
NovartisEntresto$348$44,76047 claims
Johnson & JohnsonXarelto$72$34,82527 claims
AstraZenecaBrilinta, Farxiga$337$25,65828 claims
Boehringer IngelheimJardiance$183$14,39814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →